|07/29/15||The Medicines Company Reports Second-Quarter and First-Half 2015 Financial Results|
|Commercial resources focused on new product launches
R&D investment in potential blockbusters continues
Company contracts with Sandoz for launch of authorized generic
Company exploring strategic-partnering options to accelerate
business development and unlock value
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 29, 2015--
The Medicines Company (NASDAQ:MDCO) today... |
|07/13/15||The Medicines Company to Announce Second Quarter Financial Results on Wednesday July 29, 2015|
|Conference Call to be held at 8:30 a.m. Eastern Time
PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 13, 2015--
The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly
conference call for Wednesday, July 29th at 8:30 a.m. Eastern
Time to discuss second quarter financial results, operational
developments and outlook for 2015.
The conference call will be available via phone and webcast. The dial-in
information is listed below:
|07/09/15||The Medicines Company Authorizes Generic Launch of ANGIOMAX® (bivalirudin)|
|PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 9, 2015--
The Medicines Company (NASDAQ:MDCO) today announced an agreement with
Sandoz Inc. for the distribution of an authorized generic of ANGIOMAX®
(bivalirudin) for injection in the United States.
“Bivalirudin has become a foundation anti-thrombin for patients
undergoing PCI under The Medicines Company’s fifteen-year leadership in
the cath lab,” said Glenn Sblendorio, President and Chief Financial
|07/02/15||Federal Circuit Rules Against The Medicines Company in Angiomax® (bivalirudin) Patent Litigation|
|PARSIPPANY, N.J.--(BUSINESS WIRE)--Jul. 2, 2015--
The Medicines Company (NASDAQ:MDCO) announced the U.S. Court of Appeals
for the Federal Circuit Court has ruled against the Company in its
Angiomax® (bivalirudin) patent litigation with Hospira, Inc.
In its ruling today, the Federal Circuit held that U.S. Patent Nos.
7,582,727 (the ‘727 patent) and 7,598,343 (the ‘343 patent) are invalid.
On March 31, 2014, the U.S. District Court of Delaw... |